Market Overview

Aetna Could Outperform Market After Selloff, With Or Without Humana

Aetna Could Outperform Market After Selloff, With Or Without Humana
Related AET
12 Stocks To Watch For August 3, 2017
Earnings Scheduled For August 3, 2017
Related HUM
Look Closer, Tenet Healthcare Is Making More Progress Than It Seems
12 Stocks To Watch For August 2, 2017

Shares of Aetna Inc (NYSE: AET) are up roughly 3 percent on Tuesday trading after RBC Capital Markets upgraded its stock from Sector Perform to Outperform, boosting its price target from $159.00 to $162.00.

In a report issued Tuesday morning, analysts Frank G. Morgan, Ben Hendrix and Anton Hie explained that the upgrade was motivated by their comfort with the probability of the Humana Inc (NYSE: HUM) acquisition, and the belief that, “even without Humana, Aetna's outlook is attractive at current levels.”

Related Link: AssuredPartners Acquires Nashville Insurance Broker

Rating Re-Evaluation

They explained that the company’s stock was down (at the time of the report) more than 15 percent from the all-time high it had hit in mid-June, despite the announcement of the Humana purchase and the recent posting of “a strong beat-and-raise.” These elements combined with the recent pullback in the overall market have led the experts to re-evaluate their rating.

They continued to expound, “The organic story remains solid and long-term fundamentals are compelling. Reflecting confidence in the underlying strength of the business, management increased earnings guidance again, as it has over the past six quarters.”

The Bottom Line

Moreover, RBC’s analysis suggests the acquisition of Humana “should pass antitrust scrutiny and remains attractive even if some divestitures are required.”

Image Credit: Public Domain

Latest Ratings for AET

Aug 2017Morgan StanleyMaintainsOverweight
Aug 2017Deutsche BankMaintainsHold
Jul 2017Bank of AmericaMaintainsBuy

View More Analyst Ratings for AET
View the Latest Analyst Ratings

Posted-In: Analyst Color Long Ideas News Upgrades Health Care Price Target M&A Analyst Ratings Best of Benzinga


Related Articles (AET + HUM)

View Comments and Join the Discussion!